GleamWall
中文EN

PHAT Phathom Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1783183 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY86.8%
TTM net income YoY69.8%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
FCF margin-7.7%
EBITDA margin-9.1%

Returns

ROE—
ROA-28.4%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets200.8%
Debt / equity—
Current ratio1.76x
Interest coverage-0.41x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-21.3%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$84.72M$74.27M$58.30M$57.58M$49.50M$39.50M$28.52M$29.66M
Cost of revenue$18.37M$15.10M$12.00M$7.65M$6.19M$5.04M$3.72M$3.81M
Gross profit$66.36M$59.18M$46.30M$49.94M$43.31M$34.47M$24.80M$25.85M
R&D expense$8.74M$7.81M$7.77M$7.49M$7.03M$9.08M$9.18M$8.58M
SG&A expense$57.70M$55.33M$54.01M$48.37M$51.56M$85.31M$94.47M$76.68M
Operating income-$85,000-$3.96M-$15.48M-$5.93M-$15.27M-$59.92M-$78.86M-$59.42M
Interest expense$15.39M$15.10M$15.80M$16.42M$16.11M$17.52M$18.07M$18.59M
Net income-$13.90M-$17.58M-$30.37M-$21.15M-$29.97M-$75.81M-$94.32M-$74.45M
EBITDA$35,000-$3.85M-$15.37M-$5.80M-$15.12M-$59.75M-$78.69M-$59.22M
EPS (basic)-0.16-0.21-0.37—-0.41-1.05-1.31—
EPS (diluted)-0.16-0.21-0.37—-0.41-1.05-1.31—
Weighted avg. shares (diluted)84.89M83.75M82.05M—73.40M72.47M71.97M—
Balance sheet
Cash & equivalents$184.56M$182.48M$180.90M$129.97M$135.16M$149.57M$212.31M$297.26M
Receivables$107.60M$97.42M$80.72M$78.13M$55.79M$51.26M$36.36M$38.80M
Inventory$7.63M$7.71M$6.51M$5.52M$3.61M$3.43M$3.17M$3.21M
Current assets$308.01M$295.92M$276.57M$228.97M$207.78M$218.88M$264.90M$360.13M
PP&E, net$935,000$971,000$1.02M$1.06M$1.16M$1.24M$1.35M$1.48M
Total assets$345.02M$327.07M$305.12M$259.15M$240.29M$250.22M$294.21M$378.32M
Current liabilities$174.90M$153.78M$125.04M$132.04M$93.12M$91.82M$74.03M$85.73M
Short-term debt$0$0$0$0$0$0$0$0
Long-term debt$165.54M$164.59M$163.68M$209.09M$207.09M$205.14M$203.25M$201.41M
Total debt$165.54M$164.59M$163.68M$209.09M$207.09M$205.14M$203.25M$201.41M
Total liabilities$692.66M$671.35M$642.08M$697.32M$662.82M$656.05M$632.58M$631.90M
Shareholders' equity-$347.64M-$344.27M-$336.95M-$438.17M-$422.53M-$405.83M-$338.38M-$253.58M
Net debt-$19.02M-$17.89M-$17.23M$79.11M$71.94M$55.57M-$9.07M-$95.85M
Shares outstanding81.22M80.07M79.44M71.42M71.04M70.10M69.64M68.52M
Cash flow statement
Operating cash flow$1.84M-$1.93M-$15.65M-$5.00M-$14.12M-$62.73M-$84.93M-$63.46M
Capital expenditure$110,000$44,000$61,000$87,000$27,000$97,000$18,000$5,000
Free cash flow$1.73M-$1.97M-$15.71M-$5.09M-$14.14M-$62.83M-$84.95M-$63.46M
Investing cash flow-$110,000-$44,000-$61,000-$87,000-$27,000-$97,000-$18,000-$5,000
Financing cash flow$351,000$3.55M$66.64M-$97,000-$271,000$80,000$0$26.05M
Depreciation & amortization$120,000$114,000$110,000$128,000$156,000$172,000$177,000$193,000
Stock-based compensation$5.92M$6.71M$5.53M$5.61M$9.30M$8.27M$5.54M$6.69M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.